Human papillomavirus 16 and 18 L1 serology compared across anogenital cancer sites.
Human papillomavirus (HPV) DNA has been detected in the great majority of cancers of the uterine cervix and anus, whereas the association of HPV DNA with cancer at other anogenital sites has produced less consistent results. This study was designed to compare HPV exposure among anogenital cancer cases and matched controls. Cases (1782) of anogenital cancer diagnosed in the Seattle area from 1978 to 1998 were identified and interviewed. Their responses were compared with those of 2383 age- and sex-matched controls. Blood was drawn at interview from both cases and controls and tested for antibodies to HPV-16 and HPV-18. Tissue blocks were tested for HPV DNA for 649 cases. Serum antibodies to HPV-16 were associated with in situ and invasive cancer at all sites among men and women with the exception of in situ penile cancer. Anti-HPV-18 antibodies were associated with cancers at all sites among women. The increased risk of cancer associated with HPV-16 seropositivity ranged from odds ratio = 1.8 (95% confidence interval, 1.4-2.5) for adenocarcinoma of the cervix to odds ratio = 5.9 (95% confidence interval, 3.4-10.3) for anal cancer in men. Associations between seroprevalence and cancers were stronger when analyses were restricted to HPV-16- or HPV-18 DNA-positive cases. HPV DNA was detected in >80% of cancers from all sites tested. HPV-16 DNA was the type most frequently detected at all sites (range, 40.9-82.2%). HPV-18 DNA was detected in 44.7% of adenocarcinomas of the cervix but detected much less often (2.6-18.1%) at other sites. These findings support an important role for HPV infection in anogenital cancer at all sites. Differences in the proportion of seropositives among HPV-16 DNA-positive cases by site suggest either that the immune response varies by site or that cancer development may lead to changes in antibody responses in a site-specific fashion.
Program in Cancer Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109-1024, USA.
J J
JJ
Carter
M M
MM
Madeleine
K
K
Shera
S M
SM
Schwartz
K L
KL
Cushing-Haugen
G C
GC
Wipf
P
P
Porter
J R
JR
Daling
J K
JK
McDougall
D A
DA
Galloway
D000230:Adenocarcinoma / Q000097:blood / Q000276:immunology / Q000821:virology; D000328:Adult; D000914:Antibodies, Viral / Q000096:biosynthesis / Q000097:blood*; D001005:Anus Neoplasms / Q000097:blood / Q000276:immunology / Q000821:virology*; D002213:Capsid / Q000097:blood / Q000276:immunology; D036022:Capsid Proteins; D016022:Case-Control Studies; D004279:DNA, Viral / Q000032:analysis*; D005260:Female; D005833:Genital Neoplasms, Female / Q000097:blood / Q000276:immunology / Q000821:virology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009856:Oncogene Proteins, Viral / Q000097:blood / Q000276:immunology; D027383:Papillomaviridae / Q000235:genetics* / Q000276:immunology*; D030361:Papillomavirus Infections / Q000097:blood / Q000150:complications* / Q000276:immunology; D010412:Penile Neoplasms / Q000097:blood / Q000276:immunology / Q000821:virology*; D016133:Polymerase Chain Reaction; D016036:Seroepidemiologic Studies; D014412:Tumor Virus Infections / Q000097:blood / Q000150:complications* / Q000276:immunology
D000914:Antibodies, Viral; D036022:Capsid Proteins; D004279:DNA, Viral; D009856:Oncogene Proteins, Viral; C063317:L1 protein, Human papillomavirus type 16